By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Max-Dohrn-Strasse 8-10

Berlin    10589  Germany
Phone: 49-30-726247-0 Fax: 49-30-726247-225



Drug Discovery

Company News
New Addition To NOXXON Pharma AG Supervisory Board Brings Significant U.S. Public Market Expertise 12/10/2014 8:55:20 AM
NOXXON Pharma AG Release: Phase IIa Results For Spiegelmer Olaptesed Pegol (NOX-A12) In MM And CLL At 2014 American Society of Hematology Conference 12/5/2014 1:31:25 PM
NOXXON Pharma AG Spiegelmer® Receives FDA Orphan Drug 9/23/2014 8:58:58 AM
NOXXON Pharma AG Expands Management Team By Appointing Don Munoz As Chief Financial Officer 9/18/2014 9:29:20 AM
Two Presentations At International Conferences Of Preclinical Data On NOXXON Pharma AG’s anti-C5a Spiegelmer®, A Potential Drug In Pneumococcal Pneumonia-Induced Sepsis 9/4/2014 9:32:31 AM
NOXXON Pharma AG Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hyporesponsive Anemia 7/31/2014 9:26:41 AM
NOXXON Pharma AG Presents Updates On Phase II Studies With Olaptesed Pegol (NOX-A12) In CLL And MM And Lexaptepid Pegol (NOX H94) In Anemic Cancer Patients 6/13/2014 9:55:04 AM
NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference 6/2/2014 10:45:37 AM
NOXXON Pharma AG Release: Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin In Subset Of Anemic Patients In Pilot Phase 2a Study 4/8/2014 9:30:45 AM
NOXXON Pharma AG Presents Positive Results From Emapticap Pegol Phase 2a Diabetic Nephropathy Study 4/4/2014 7:14:02 AM